These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21528942)

  • 1. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from Twice-Daily Prograf
    Yau WP; Loh CW; Vathsala A
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5.
    Wu MJ; Chang CH; Cheng CY; Shu KH; Chen CH; Cheng CH; Yu TM; Chuang YW; Huang ST; Tsai SF; Ho HC; Li JR; Shiu YN; Fu YC
    Transplant Proc; 2014; 46(2):403-5. PubMed ID: 24655974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
    Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
    Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.
    Woillard JB; de Winter BC; Kamar N; Marquet P; Rostaing L; Rousseau A
    Br J Clin Pharmacol; 2011 Mar; 71(3):391-402. PubMed ID: 21284698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.
    Fan B; Qiu K; Jiang Y; Hu X; Yin H; Wang W; Ren L; Liu H; Wang W; Zhang X
    Biomed Pharmacother; 2017 Apr; 88():738-744. PubMed ID: 28157649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cytochrome P450 3A5 Non-Expressor Kidney Allograft as a Risk Factor for Calcineurin Inhibitor Nephrotoxicity.
    Udomkarnjananun S; Townamchai N; Chariyavilaskul P; Iampenkhae K; Pongpirul K; Sirichindakul B; Panumatrassamee K; Vanichanan J; Avihingsanon Y; Eiam-Ong S; Praditpornsilpa K
    Am J Nephrol; 2018; 47(3):182-190. PubMed ID: 29539600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients.
    Htun YY; Swe HK; Saw TM
    Transplant Proc; 2018 May; 50(4):1034-1040. PubMed ID: 29731062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of
    Kim JM; Ryu JH; Lee KW; Hong SK; Yang K; Choi GS; Kim YA; Lee JY; Yi NJ; Kwon CHD; Chu CW; Suh KS; Joh JW
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32911703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.